Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Cocrystal Pharma, Inc. (COCP : NSDQ)
 
 • Company Description   
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of HepC. Phase 1b studies in HepC infected patients showed the largest reduction in viral load of any non-nucleoside inhibitor tested to date. The next step for CC-31244 is clinical trials as part of a cocktail for ultra-short therapy of 2 to 6 weeks. The lead candidate for influenza has advanced to IND-enabling studies. It is effective in animal models against both the pandemic and seasonal strains of influenza. In addition, the Company has a pipeline of promising early preclinical programs. Two private investors own approximately 48% of the Company.

Number of Employees: 13

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.38 Daily Weekly Monthly
20 Day Moving Average: 277,826 shares
Shares Outstanding: 97.47 (millions)
Market Capitalization: $37.04 (millions)
Beta: 1.13
52 Week High: $1.49
52 Week Low: $0.37
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -26.74% -17.50%
12 Week -30.26% -23.34%
Year To Date -41.54% -26.69%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
19805 N. CREEK PARKWAY
-
BOTHELL,WA 98011
USA
ph: 786-459-1831
fax: -
jcain@lhai.com http://www.cocrystalpharma.com
 
 • General Corporate Information   
Officers
Sam Lee - President and Co-Interim Chief Executive Officer
Roger Kornberg - Chairman
James Martin - Chief Financial Officer and Co-Interim Chief Execu
Phillip Frost - Director
Steven Rubin - Director

Peer Information
Cocrystal Pharma, Inc. (CORR.)
Cocrystal Pharma, Inc. (RSPI)
Cocrystal Pharma, Inc. (CGXP)
Cocrystal Pharma, Inc. (BGEN)
Cocrystal Pharma, Inc. (GTBP)
Cocrystal Pharma, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 19188J300
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/15/22
Share - Related Items
Shares Outstanding: 97.47
Most Recent Split Date: (:1)
Beta: 1.13
Market Capitalization: $37.04 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.04 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.16 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/15/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.50
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 0.00%
vs. Previous Quarter: 0.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -19.76
12/31/21 - -19.21
09/30/21 - -17.75
ROA
03/31/22 - -19.28
12/31/21 - -18.71
09/30/21 - -17.25
Current Ratio
03/31/22 - 35.56
12/31/21 - 38.40
09/30/21 - 50.85
Quick Ratio
03/31/22 - 35.56
12/31/21 - 38.40
09/30/21 - 50.85
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -2,351.57
Book Value
03/31/22 - 0.75
12/31/21 - 0.80
09/30/21 - 0.83
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.01
09/30/21 - 0.02
 

Powered by Zacks Investment Research ©